Crossmark

IMMUNE PROFILING EVALUATION OF NEWLY DIAGNOSE MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS TREATED WITH DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (DARA-CTD): PRELIMINARY RESULTS

Crossref DOI link: https://doi.org/10.1016/j.htct.2020.10.437

Published Print: 2020-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Santos, A.S.

Santos, H.H.M.

Salvino, M.A.

Silva, S.Q.

Lucas, L.F.

Almeida, A.M.

Santos, M.M.

Arruda, M.G.B.

Torres, A.J.L.

Crusoe, E.Q.
License Information

Text and Data Mining valid from 2020-11-01

Version of Record valid from 2020-10-13
More Information

This article is maintained by: Elsevier

Article Title: IMMUNE PROFILING EVALUATION OF NEWLY DIAGNOSE MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS TREATED WITH DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (DARA-CTD): PRELIMINARY RESULTS

Journal Title: Hematology, Transfusion and Cell Therapy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.htct.2020.10.437

Content Type: simple-article

Copyright: Copyright © 2020 Published by Elsevier Editora Ltda.

Document is current

Any future updates will be listed below